Medacta Group SA

Medacta Group SA revenues up +19.5% at constant currency1 exceeding the milestone of 500Mln € in FY 2023 - Seite 3

* EMEA and Latin America (LATAM): In 2023 we reorganized the key geographic areas introducing EMEA and LATAM regions, reclassifying Rest of the World (RoW) region. EMEA includes revenue from the former Europe region and certain countries originally included in RoW region. LATAM includes revenue from countries located in Latin America which were previously included in RoW. 2022 figures have been restated accordingly.
             

Hip products increased revenue by 15.5% c.c., to Euro 229.8 million, with good performance in all geographies mainly driven by our Anterior Minimally Invasive Surgery Approach (AMIS) and Hip revision.

Revenue from our Knee offerings grew in every market by 23.2% c.c. to Euro 198.3 million, thanks to a solid and complete product offering based on our personalized kinematic alignment solutions (MyKA).

Our Extremities business line reported an increase in revenue of 33.8% c.c., to Euro 36.3 million, primarily attributable to Shoulder through the Medacta Shoulder System and Technologies (MyShoulderand NextAR). The Sportsmed business, which is in an early start-up phase, continued to develop its growth plan.

Revenue from our Spine offering increased by 15.2% c.c. to Euro 46.4 million, driven by performance recorded in EMEA and North America. Growth in APAC was partially offset by price cuts in Japan. Good acceleration seen on NextAR Spine utilization, recently supported by a clinical study which highlights its efficiency in spine surgery.

Below we report the FY2023 sales break-down by product line:

(Million Euro)	FY 2023	FY 2022	Reported Growth	Constant Currency Growth
Hip	229.8	203.6	12.9%	15.5%
Knee	198.3	164.5	20.6%	23.2%
Extremities*	36.3	27.5	31.9%	33.8%
Spine	46.4	41.5	11.7%	15.2%
TOTAL	510.8	437.1	16.8%	19.5%